What Is Coxsackievirus A16 and How Does It Spread?

Coxsackievirus A16 (CVA16) is a small, non-enveloped RNA virus in the enterovirus family, and it is one of the two leading causes of hand, foot, and mouth disease (HFMD) worldwide. It spreads through direct contact with an infected person’s saliva, nasal secretions, blister fluid, or stool, and it can also survive on contaminated surfaces long enough to pass from one person to another indirectly. Although most CVA16 infections are mild and self-limiting, the virus circulates widely in young children, and the biology of how it enters cells and how long it persists in the environment shapes the practical steps that matter for prevention.

How CVA16 Gets Into Your Cells

CVA16 is a picornavirus, meaning it is tiny even by viral standards. Its outer shell, or capsid, is built from repeating protein subunits arranged in a symmetric sphere. Structurally, CVA16 is closely related to enterovirus A71 (EV-A71), the other major HFMD pathogen, and also to coxsackievirus A6 and A10. These viruses share more than 69% of their genetic sequence, and the shapes of their capsid building blocks can be overlaid almost perfectly.¹ Despite that similarity, the immune system treats them as distinct: antibodies raised against one do not reliably neutralize the other.

To infect a cell, CVA16 uses a two-step entry process. First, it latches onto heparan sulfate, a sugar-based molecule that coats the surface of many human cells. Research has identified a cluster of positively charged amino acids at the tip of the virus particle that are responsible for this initial grip, with one residue in particular (arginine at position 166 on the VP1 protein) being critical.² After attachment, the virus engages a second receptor called SCARB2, which helps it shed its capsid and release its genetic material inside the cell.³ This two-receptor system is one reason the virus targets specific tissues, particularly the lining of the mouth, skin of the hands and feet, and, in rare cases, neurons.

Routes of Transmission

CVA16 spreads through several overlapping routes, and which route dominates depends partly on local conditions. In settings with poor sanitation, the fecal-oral route tends to be the main driver: the virus replicates in the gut and is shed in stool for weeks after symptoms resolve, contaminating hands and shared objects. In settings with better sanitation, respiratory transmission becomes relatively more important, with the virus traveling in droplets from coughs, sneezes, and the saliva of infected children.⁴ Fluid from the blisters that appear on the hands, feet, and mouth is also highly infectious on direct contact.

In practice, this means the virus spreads efficiently wherever young children are in close quarters. One outbreak investigation at a preschool in Taipei documented CVA16 infecting roughly 62% of children in the affected class within about two weeks, and compared to outbreaks caused by related coxsackieviruses A2 and A4, CVA16 had a significantly higher transmission rate.⁵ The transmission period within a single classroom ranged from 12 to 40 days in those investigations, depending on the virus involved. Diaper changes, shared toys, and mouthing of objects all accelerate spread in daycare and preschool settings.

How Long the Virus Lasts on Surfaces

One reason CVA16 spreads so readily indoors is that it can survive on everyday surfaces for hours. Lab experiments testing the virus on different materials found that CVA16 lost about 80% of its infectivity on plastic within three hours but held up better on wood and stainless steel, retaining more than half its infectivity after four hours on those surfaces.⁶ That means a contaminated doorknob, countertop, or toy can plausibly pass the virus to the next person who touches it and then touches their mouth or nose. Heat destroys the virus effectively: incubation at 60°C (140°F) for 15 minutes eliminated detectable infectious virus entirely.⁶

For chemical disinfection, standard household bleach works well. Testing against both CVA16 and EV-A71 showed that a five-minute exposure to sodium hypochlorite at roughly 3,120 parts per million completely inactivated both viruses.⁷ That concentration is stronger than a typical household spray but is easily mixed from concentrated bleach. Alcohol-based hand sanitizers are less reliable against non-enveloped viruses like CVA16, which is why public health authorities emphasize soap-and-water handwashing over gel sanitizers for HFMD prevention.

What an Infection Looks Like

Most CVA16 infections produce the classic hand, foot, and mouth disease pattern. After an incubation period of roughly three to five days, symptoms typically begin with fever and a sore throat or mouth pain, followed by a distinctive rash. In one documented outbreak in Granada, Spain, caused by CVA16, the most common findings were fever (75% of cases), blisters on the palms (71%), blisters on the soles (68%), and painful mouth sores (64%).⁸ The same outbreak reported nail shedding (onychomadesis) in 46% of affected children, a phenomenon that can alarm parents but is painless and temporary: nails grow back normally over several weeks.

Blisters are small, oval, and fluid-filled, usually appearing on the fingers, backs of the hands, sides of the feet, and sometimes on the buttocks or legs. The mouth sores, often called herpangina when they cluster near the back of the throat, make eating and drinking painful, which is usually the main source of misery for toddlers. Most children recover fully within seven to ten days, though viral shedding in stool continues well beyond that window.

Who Gets Infected

CVA16 overwhelmingly affects young children, particularly those under five. An early epidemiological investigation in Baltimore during a 1968 outbreak found that 75% of patients with confirmed CVA16 were younger than five, though 53% of positive family contacts were adults.⁹ Adults who contract CVA16 are often asymptomatic or have such mild symptoms that they never seek medical care, yet they can still shed virus and spread it to others. This silent adult transmission is one reason outbreaks in childcare centers are difficult to contain: a parent or staff member may carry the virus home or between classrooms without knowing it.

Geographically, CVA16 circulates globally but causes the largest documented outbreaks in the Asia-Pacific region. Molecular surveillance in southern China showed that CVA16 infections were continuously high from 2008 to 2014, dipped between 2015 and 2017, and then surged again in 2018 and 2019, a pattern that did not follow a simple predictable cycle.¹⁰ In temperate climates, outbreaks tend to peak in late spring and summer, while tropical regions may see year-round circulation.

CVA16 Versus EV-A71

CVA16 and enterovirus A71 are often discussed together because they are the two most common causes of HFMD and look clinically similar in uncomplicated cases. The critical difference is severity. During Taiwan’s large 1998 enterovirus epidemic, researchers directly compared the two: 94% of CVA16 cases were uncomplicated, with only about 6% developing aseptic meningitis and no fatalities or lasting neurological problems. EV-A71, by contrast, produced complications in 32% of cases, including encephalitis, polio-like paralysis, and fatal pulmonary edema, with a fatality rate of about 8%.¹¹

A study from Shanghai examining severe HFMD cases found that both viruses frequently caused high fevers above 39°C, but warning signs such as vomiting, involuntary jerking movements, and exaggerated startle reflexes were significantly more common in EV-A71 infections than in CVA16 cases.¹² These differences matter for clinical triage: a child with HFMD who develops persistent vomiting, jerking, or lethargy needs urgent evaluation, and rapid identification of the causative virus can guide how aggressively to monitor them.

Can CVA16 Cause Serious Neurological Problems?

Though CVA16 is far less dangerous than EV-A71, labeling it “always mild” would be an overstatement. Animal research has confirmed that CVA16 is neurotropic, meaning it has an affinity for nerve cells. In hamsters infected orally with CVA16, the virus was found in brainstem neurons and in the motor neurons of the spinal cord, the same cells that control voluntary movement.¹³ This preference for motor neurons explains the occasional reports of acute flaccid paralysis and encephalitis in human CVA16 infections.

Side-by-side comparisons in mouse models found that CVA16 does produce neurological damage but requires a higher viral dose to do so than EV-A71, and the density of virus in the brain and spinal cord is lower. The lethal dose for CVA16 was higher than for EV-A71, confirming that CVA16 is less neurovirulent but is not harmless to the nervous system.¹⁴ The virus appears to reach the central nervous system by hitching a ride backward along peripheral motor nerves, a mechanism called retrograde axonal transport. In practice, neurological complications from CVA16 remain rare in humans, but they are documented, and parents should not assume that HFMD is always trivial if symptoms escalate.

How CVA16 Is Diagnosed

In most outpatient settings, HFMD is diagnosed clinically based on the characteristic rash and mouth sores. No lab test is needed for a straightforward case in an otherwise healthy child. However, when complications arise, when surveillance teams are tracking an outbreak, or when clinicians need to distinguish CVA16 from EV-A71 for prognostic reasons, molecular testing becomes important.

The standard approach uses real-time reverse-transcription PCR (RT-PCR), which amplifies and detects specific genetic sequences from throat swabs or stool samples. Multiplex versions of this test can identify CVA16, EV-A71, and coxsackievirus A6 simultaneously in a single run, with reported sensitivity around 99% and specificity above 99.9% for CVA16.¹⁵ These assays can detect as few as 10 copies of viral genetic material per microliter of sample, making them powerful tools for outbreak surveillance.¹⁶ For most families, the practical message is that a lab test is rarely necessary for a mild case but can be obtained quickly if the clinical picture warrants it.

The Evolving Genetics of CVA16

Like most RNA viruses, CVA16 mutates and recombines frequently. Phylogenetic analysis of hundreds of CVA16 sequences has identified several genotypes. The most important globally is subgenotype B1, specifically a cluster called B1b, which has been the dominant circulating strain for years.¹⁷ An older subgenotype, B2, circulated from the early 1980s through 2000 and then disappeared from surveillance databases. More recently, a genotype called D has emerged, and genomic evidence points to it being a recombinant that incorporated genetic material from multiple CVA16 lineages.¹⁸

One reassuring finding is that while recombination reshuffles the non-structural parts of the genome quite extensively, the structural proteins that form the capsid, and that the immune system targets, remain relatively conserved.¹⁹ That stability is good news for vaccine developers, because it means a vaccine designed against one strain’s surface proteins has a reasonable chance of working against other circulating strains.

Where Things Stand on a Vaccine

Several inactivated EV-A71 vaccines have been licensed in China, but as of now, there is no licensed CVA16 vaccine for use in humans.²⁰ This gap matters because the EV-A71 vaccines do not protect against CVA16. Studies have consistently shown that antibodies generated against one of these viruses have little or no neutralizing effect on the other.²¹ Even more concerning, one mouse study found that antibodies raised against CVA16 alone could cause antibody-dependent enhancement of disease when the animals were challenged with EV-A71, meaning the immune response actually made a subsequent EV-A71 infection worse rather than better.

This has pushed researchers toward bivalent vaccines that target both viruses simultaneously. In mice, a combined EV-A71 and CVA16 virus-like particle vaccine eliminated the enhancement problem and provided full protection against lethal doses of either virus.²¹ Inactivated whole-virus CVA16 candidates have also shown promise in gerbils and mice, producing robust neutralizing antibody responses and cross-protecting against multiple clinical strains.²² Chimeric approaches that graft CVA16 surface epitopes onto an EV-A71 particle scaffold have shown the ability to boost cross-reactive immunity as well.²³ All of these remain preclinical, so a human CVA16 vaccine is still likely years away, but the pipeline is active.

The Economic Burden on Families

Because HFMD is so common in young children and because outbreaks trigger childcare and school closures, the economic cost extends well beyond medical bills. A study across multiple regions in China estimated total costs per case at roughly $196 for a mild outpatient visit but climbing to about $990 for a mild inpatient stay and over $3,000 for a severe case, with direct medical costs making up the majority.²⁴

Lost parental wages are a significant hidden cost. In Shanghai, parents of outpatient HFMD children missed an average of about 2.6 work days, while parents of children hospitalized with severe disease missed roughly 15.5 days.²⁵ Those figures undercount the real impact, because they do not include parents whose healthy children were kept home when a daycare center or school shut down as a containment measure. In 2011, HFMD clusters in Shanghai led to the closure of over 1,350 school classes and 70 kindergarten centers, potentially affecting more than 41,000 families.²⁵ The ripple effects on working parents, especially those without paid sick leave, make HFMD outbreaks a meaningful economic event at the community level, even though the illness itself is usually mild.

Practical Prevention Without a Vaccine

Until a vaccine becomes available, prevention is entirely about hygiene and environmental control. Frequent handwashing with soap and water is the single most effective measure, particularly after diaper changes and before meals. Alcohol-based sanitizers are a poor substitute here because CVA16 lacks the lipid envelope that alcohol disrupts in viruses like influenza. Surfaces in childcare settings, especially high-touch items like toys, changing tables, and door handles, should be cleaned with dilute bleach solutions. Given that the virus can survive for hours on wood and metal, wiping down shared surfaces multiple times per day during outbreaks is not excessive.

Keeping a sick child home is important, but the challenge is timing. Children are most contagious during the first week of illness, when blisters are present and viral levels in saliva and stool are highest. However, stool shedding continues for weeks after symptoms resolve, so strict isolation for the entire shedding period is rarely practical. Most guidelines recommend keeping children home until fever has resolved and mouth and hand sores have dried, typically about a week. Teaching children to cover coughs, avoid sharing cups or utensils, and wash hands after using the toilet rounds out the prevention toolkit. None of these measures are novel, but together they are the best defense available against a virus that exploits the combination of close contact and incomplete hygiene that defines life in a preschool classroom.